THURSDAY, SEPTEMBER 4, 2025

SATELLITE SYMPOSIUM
THURSDAY, SEPTEMBER 4, 2025, 11.35 am – 12.35 pm
Current and Upcoming Treatment Strategies After CDK4/6i for Patients with ER+/HER2- Advanced Breast Cancer
Chair:  S. Kümmel
Liquid Biopsy – the Essentials to Detect ESR1-Mutations
M. Graf
Guideline Recommendations and Implementation in Clinical Practice
N. Harbeck
Case Reports and Plenum Discussion
S. Kümmel
Take-Home Message
S. Kümmel
With the kind support of
Menarini Stemline Deutschland GmbH
SATELLITE SYMPOSIUM
THURSDAY, SEPTEMBER 4, 2025, 02.30 - 03.30 pm
Tailoring Patient-Individual Treatments: Biomarker-Guided Strategies in Breast Cancer and Gynaecological Oncology
Chair:  S. Kümmel, P. Harter
HR+, HER2- Metastatic Breast Cancer
B. Jäger
Discussion
Endometrial Cancer and Ovarian Cancer
S. Mahner
Discussion
With the kind support of
AstraZeneca GmbH

FRIDAY, SEPTEMBER 5, 2025

SATELLITE SYMPOSIUM
FRIDAY, SEPTEMBER 5, 2025, 12.40 - 01.40 pm
Innovative Therapies and Collaborative Strategies in Ovarian Cancer Management
Chair:  F. Hilpert
Therapeutic Utility of ADCs and Biomarker Testing for Ovarian Cancer Patients
L. Hanker
Interdisciplinary Therapy Management of PROC Patients
F. Hilpert, M. Groeben
Take-Home Message
P. Harter
With the kind support of
AbbVie Deutschland GmbH & Co. KG
SATELLITE SYMPOSIUM
FRIDAY, SEPTEMBER 5, 2025, 03.30 – 04.30 pm
Update on Immuno-Oncologic Treatment Strategies in Gynaecologic Cancers
Chair:  P. Harter
The Relevance of Immunotherapy in Cervical Cancer
F. Marmé
Interdisciplinary Therapy Management of PROC Patients
F. Hilpert, M. Groeben
ESGO/ESTRO/ESP Guideline Advanced Endometrial Cancer – What is New?
N. Concin
With the kind support of
MSD Sharp & Dohme GmbH

SATURDAY, SEPTEMBER 6, 2025

SATELLITE SYMPOSIUM
SATURDAY, SEPTEMBER 6, 2025, 08.45 – 09.30 am
A Panoptic View: From Early Detection to Metastasis in HR+/HER2- Breast Cancer
Chair:  S. Kümmel
Case Introduction
n.n.
Early Detection, Recurrence Risk – Therapeutic Implications?
n.n.
Visceral Metastasis – What Now?
M. Banys-Paluchowski
Panel Discussion and Closing
M. Banys-Paluchowski
With the kind support of
Novartis Pharma GmbH
SCIENTIFIC SYMPOSIUM
SATURDAY, SEPTEMBER 6, 2025, 11.40 am -12.40 pm
ADCs Debut in 1st Line mBC: Navigating Sequencing Challenges
Chair:  S. Kümmel
Setting New Standards for HER2+ 1st Line
N. Harbeck
ADCs in HR+: State of the Art, Sequencing Future Trends
P. Schmid
With the kind support of
Daiichi Sankyo Deutschland GmbH